Kangzhi Pharmaceutical: Concentrated procurement with specified quantity in the cold-clearing granules.

Kangzhi Pharmaceutical announced that its product, Cold-Relief Granules, has been successfully selected for centralized procurement by the National Consortium of Chinese Patent Medicine. The centralized procurement period will be from the date of the selection results to December 31, 2028. The first-year procurement demand of each purchasing group will be determined by the cumulative purchasing demand actually reported by medical institutions in the alliance regions participating in this centralized procurement. The specific procurement volume of the company will be subject to the formal documents and procurement agreements in the future. The selection of Cold-Relief Granules in this centralized procurement is beneficial for the company to further enhance its market share, strengthen its market competitiveness and brand influence in the field of cold medicine, and have a positive impact on the company's long-term business development.